Titre : Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection
link : Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection
Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection
Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infectionSwee Lin G. Chen Yi Mei , Alexander J. Thompson, Britt Christensen, Georgina Cunningham, Lucy McDonald, Sally Bell, David Iser, Tin Nguyen, Paul V. Desmond
Published: October 24, 2017 http://ift.tt/2yKSId4
Full-Text
Download PDF
View Online
Abstract
Background/Aims
Long-term follow-up studies validating the clinical benefit of sustained virological response (SVR) in people with chronic hepatitis C (CHC) infection are lacking. Our aim was to identify rates and predictors of liver fibrosis progression in a large, well characterized cohort of CHC patients in whom paired liver fibrosis assessments were performed more than 10 years apart.
Methods
CHC patients who had undergone a baseline liver biopsy pre-2004 and a follow up liver fibrosis assessment more than 10 years later (biopsy or liver stiffness measurement (LSM) using transient elastography [FibroScan]) were identified. Subjects who had undergone a baseline liver biopsy but had no follow up fibrosis assessment were recalled for LSM. Fibrosis was categorised as mild-moderate (METAVIR F0-2 / LSM result of ≤ 9.5 kPa) or advanced (METAVIR F3-4/ LSM >9.5 kPa). The primary objective was to assess the association between SVR and the rate of liver fibrosis progression over at least 10 years, defined as an increase from mild-moderate fibrosis at baseline liver biopsy (METAVIR F0-2) to advanced fibrosis at follow-up liver fibrosis assessment.
Results
131 subjects were included in this analysis: 69% male, 82% Caucasian, 60% G1 HCV, 25% G3 HCV. The median age at F/U fibrosis staging was 57 (IQR 54–62) years with median estimated duration of infection 33-years (IQR 29–38). At F/U, liver fibrosis assessment was performed by LSM in 86% and liver biopsy in 14%. The median period between fibrosis assessments was 14-years (IQR 12–17). 109 (83%) participants had received interferon-based antiviral therapy. 40% attained SVR. At F/U, there was a significant increase in the proportion of subjects with advanced liver fibrosis: 27% at baseline vs. 46% at F/U (p = 0.002). The prevalence of advanced fibrosis did not change among subjects who attained SVR, 30% at B/L vs 25% at F/U (p = 0.343). However, advanced fibrosis became more common at F/U among subjects with persistent viremia: 10% at B/L vs 31% at F/U (p = 0.0001). SVR was independently associated with protection from liver fibrosis progression after adjustment for other variables including baseline ALT (p = 0.011), duration of HCV infection and mode of acquisition.
Conclusion
HCV eradication is associated with lower rates of liver fibrosis progression. The data support early treatment to prevent long-term liver complications of HCV infection.
Thus articles Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection
that is all articles Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection the link address https://newsaninpiration.blogspot.com/2017/10/sustained-virological-response-halts.html
0 Response to "Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection"
Post a Comment